Inflammatory bowel disease (IBD) is a complex chronic inflammatory disease, with pathogenesis involving genetic susceptibility, epithelial barrier dysfunction, immune dysregulation, and gut microbiota disorder. Research has shown that gut microbiota and its metabolites play a crucial role in the occurrence and progression of IBD. Metabolomics, as an important technique for analyzing host and microbial metabolites, not only contributes to a deeper understanding of IBD pathophysiology, but also could develop into characterization of biomarkers for diagnosis and IBD treatment response. Numerous studies have demonstrated significant differences between IBD patients and healthy individuals in multiple metabolites, including short-chain fatty acids (SCFAs), bile acids, sphingolipids, and polyunsaturated fatty acids. Based on the inclusion of more relevant literature, this study aims to conduct a meta-analysis to investigate alterations in SCFAs in IBD patients. And for the first time, a systematic evaluation of the lipid composition characteristics of IBD patients was conducted, providing a basis for further revealing the metabolic mechanism and potential therapeutic targets of IBD.